Saturday, February 11, 2006


Viral Hepatitis C - Inovio Biomedical to Develop Vaccine for Hepatitis C in Partnership with Tripep AB


Inovio Biomedical to Develop Vaccine for Hepatitis C in Partnership with Tripep AB
[Press Release] Business Wire via Yahoo! Finance - Jan 17 3:00 AM
SAN DIEGO----Jan. 17, 2006--Inovio Biomedical Corporation , a late stage developer of cancer and other therapies using electroporation to deliver drugs and nucleic acids, announced today that it has signed an agreement with Swedish-based Tripep AB to develop a therapeutic vaccine for hepatitis C virus .Save to My Web

Schering-Plough Initiates PEG-INTRON(R) Maintenance Study In Patients Coinfected With Hepatitis C And HIV
Medical News Today - Jan 15 4:17 PM
Schering-Ploughannounced today that it is initiating a large multinational clinical trial toevaluate the use of low-dose PEG-INTRON(R) (peginterferon alfa-2b) maintenancemonotherapy in preventing or delaying hepatitis C disease progression and thuspotentially reducing the occurrence of clinical events such as livertransplantation, liver cancer and death in cirrhotic patients with hepatitis Cwho Save to My Web

Schering-Plough Drug Gets Fast Track
AP via Yahoo! Finance - Jan 30 6:44 AM
Drug maker Schering-Plough Corp. said Monday that regulators granted "fast track" status to its experimental hepatitis C treatment.Save to My Web

YOU ARE HERE:
Aidsmap - Jan 18 6:06 AM
In order to improve response to hepatitis C virus (HCV) treatment, individuals coinfected with HIV and HCV should increase their dose of ribavirin ( Copegus / Rebetol / Virazole ), according to two presentations to the Second International Workshop on HIV and Hepatitis Coinfection, held in Amsterdam last week.Save to My Web

Hepatitis C Patients Taxing Medical System
MedicineNet.com - Jan 27 4:21 AM
Title: Hepatitis C Patients Taxing Medical System Category: Health News Created: 12/31/2005 1:59:00 AM Last Editorial Review: 12/31/2005 1:58:37 AMSave to My Web

Viral Hepatitis C - Schering-Plough Drug Gets Fast Track


Schering-Plough Drug Gets Fast Track
MSN MoneyCentral - KENILWORTH, N.J. (AP) - Drug maker Schering-Plough Corp. said Monday that regulators granted "fast track" status to its experimental hepatitis C treatment. The Food and Drug Administration gives the fast track label -- which sometimes helps speed the

Aethlon Medical Announces Avian Flu Treatment Application
Genetic Engineering News - Aethlon Medical, Inc., (OTCBB:AEMD), a pioneer in developing therapeutic devices for infectious disease, announced today that it is expanding the applications of its Hemopurifier(TM) treatment technology to include the H5N1 strain of the Avian Flu

Viral Hepatitis and HIV Coinfection
Medscape News - In Western countries, chronic HBV infection affects 5% to 10% of HIV-positive individuals. However, a larger proportion of the HIV-infected population has been exposed to HBV in the past. Isolated hepatitis B core antibody (anti-HBc) is more common

FDA Grants Fast Track Designation To Oral HCV Protease Inhibitor SCH
Medical News Today - Schering-Plough today reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational oral hepatitis C protease inhibitor (SCH 503034), currently in Phase II clinical development for the treatment

Home paper shredders pose serious injury risk to toddlers
RxPG - By New York University Medical Center and School of Medicine, As our environments change over time with technology, pediatric emergency specialists are continuously challenged to observe possible trends and prevent more injuries by educating the

Friday, February 10, 2006


Viral Hepatitis C - National HCV Prison Coalition - Hepatitis C Awareness Project


National HCV Prison Coalition - Hepatitis C Awareness Project
The National Hepatitis C Prison Coalition provides support to prison inmates who are suffering from hepatitis C (HCV) and HIV/HCV coinfection. The coalition is an affiliation of organizations and individuals committed to raising awareness, ... prisoners who are suffering from hepatitis and HIV/HCV coinfection. Our goal is to help educate ...

Laboratory Tests and HCV
serologic Assays and the Assessment of HCV Viremia. This document is primarily directed at the VA healthcare provider. ... It is performed with the use of antigens from the HCV genome combined with patient's serum ... individual with a positive anti-HCV and negative HCV-RNA, RIBA can help confirm ...

Serologic Tests Used to Diagnose Hepatitis C
... diagnosis of hepatitis C is to test for HCV RNA using a sensitive polymerase chain reaction (PCR) assay ... test negative for anti-HCV despite having HCV infection because they may ...

HCV-Genotype
There are 11 different Genotypes to Hepatitis C and at least 50 different Sub-types. These numbers seem to grow as researchers find more and more Genotypes and sub-types around the world. ... genotype you have, you should be given an HCV RNA PCR Quantitative test at the 24 week mark ... have suggested that a person's HCV subtype (or subtypes) may influence their ...

Thursday, February 09, 2006


Viral Hepatitis C - Schering-Plough drug gets fast track


Schering-Plough drug gets fast track
BusinessWeek - Jan 30, 2006... The drug, known as SCH 503034, is an oral therapy in mid-stage human studies testing it as a treatment for chronic hepatitis C infection. ...

HAART reduces liver-related death risk, but hepatitis C infection ...
Aidsmap, UK - Jan 18, 2006Highly active antiretroviral therapy (HAART) reduces the risk of liver-related death by 68%, although infection with both HIV and hepatitis C virus (HCV ...

Biomedical timeline
Knoxville News Sentinel (subscription), TN - Jan 19, 2006... permission. One tissue recipient claims she tested positive for syphilis after transplant; two claim hepatitis C infection. Dec. ...

Researchers look to re-invigorate immune system
myDNA.com, TX - Jan 13, 2006... received a grant from the Bill and Melinda Gates Foundation's Grand Challenges in Global Health program to extend their findings to hepatitis C infection. ...

Wednesday, February 08, 2006


Viral Hepatitis C - Viral Hepatitis and HIV Coinfection


Viral Hepatitis and HIV Coinfection
Medscape News - In Western countries, chronic HBV infection affects 5% to 10% of HIV-positive individuals. However, a larger proportion of the HIV-infected population has been exposed to HBV in the past. Isolated hepatitis B core antibody (anti-HBc) is more common

Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program in Acceleration
RxPG - "The initial success of our efforts to accelerate the HCV clinical trial program for Tarvacin Anti-Viral is gratifying in view of Tarvacin's promise as an important new treatment option for a number of viral infections, including chronic hepatitis C

Novartis and Idenix seek European approval of telbivudine (LDT600) for
WebWire - * Telbivudine represents a potential new standard of care for hepatitis B treatment through rapid and sustained viral suppression * US and European submissions now completed, submissions in key Asian markets planned to be completed in the first


Viral Hepatitis C - A Summary of Chronic Hepatitis C InfectionHepatitis C

A Summary of Chronic Hepatitis C Infection

Hepatitis C is a stealthy virus that mutates while hiding in liver cells and other organ cells like the spleen and gall bladder. The fact that the viral cells "hide" makes it very difficult for the body's immune system to eradicate it. Hepatitis C is a slowly progressing disease sometimes taking many years until symptoms are noticeable. It is at this point that the virus has reached advanced chronic stage and becomes difficult to eradicate. Hepatitis C results in 8,000 to 10,000 deaths annually. Hepatitis C is also the leading cause of liver transplants in the U.S.

Hepatitis C infection is caused by blood contact with someone who has the virus infection himself. The transmission of the virus can occur by illicit drug use with needles, sharing toothbrushes or razors with an infected person, by sexual means, by unsanitary tattooing or by exposure to blood at your workplace (like a hospital or blood bank). Some HCV infection may have been caused by receiving blood from a transfusion prior to 1992.

Hepatitis C is diagnosed via a blood test. Usually, the first thing that is noticed is that the liver enzyme levels for ALT and AST are elevated well above normal levels. Further investigation via HCV-RNA testing identifies whether the Hepatitis C virus is in your blood or not. Other tests for HCV include qualitative viral load tests, which measure the RNA particles in your blood. If you are being treated for HCV, your doctor is probably using either a HCV-RNA or viral load test to determine the effectiveness of the treatment.

The symptoms of Hepatitis C infection often do not occur in a person until 20 years after he/she had been infected. Since the HCV infects the liver and the liver is the organ in the body that makes all the energy for our daily activities possible, liver function deterioration often results in fatigue. Fatigue is the primary complaint or symptom of HCV infection. Other more severe symptoms are jaundice (yellowing of the skin/eyes), bile retention (which can cause jaundice), portal vein hypertension, skin rashes and itching, and autoimmune problems resulting from your body's immune system attacking normal cells.

Long term HCV infection may result in fibrosis or even cirrhosis of the liver. Fibrosis results from unchecked liver inflammation. As the HCV infection progresses, the damage to the liver results in scarring or hardening of the liver cells (fibrosis). Long term fibrosis may lead to cirrhosis which is when the scarring from fibrosis overtakes the normal liver cell structure causing deformity and loss of function in the liver. About 15%-20% of HCV patients end up with cirrhosis. A liver biopsy is currently the most accurate means of determining the amount of inflammation and fibrosis the liver has sustained.

Hepatitis C progression in the body can take several years or even decades to come to chronic stage or to a stage where severe liver damage is evident. This period of time allows a person to determine how to properly treat the disease and to decide on a course of disease management. Currently, the main treatment for HCV infection to eradicate the virus is combo alpha-interferon and Ribavirin. Sometimes a doctor may prescribe interferon alone. Interferon comes in standard form or in pegylated form. Standard form interferon is administered 3 times per week, while the pegylated form is administered only once per week. Your body makes its own interferon, which is a protein that fights viral infection and viral replication.

Hepatitis C may often be managed by taking herbal and vitamin supplements that help your body fight infection and limit inflammation. These supplements help your liver with the inflammation and give it the nutrients it needs to regenerate healthy new cells. Your doctor can recommend alternative or adjunct solutions you may want to try.

Proper treatment of the disease, a healthy and active lifestyle, a good diet, abstinence from alcohol and stress management are important factors in controlling Hepatitis C progression.

About the Author

Greg Lietz is a freelance writer and internet businessman. His main website is http://www.theonlinebizplace.com where he provides content about internet based business opportunities and different niche interests. This article may be freely printed when the bio information is included.

Tuesday, February 07, 2006


Viral Hepatitis C - Chiron Reports 2005 Adjusted Earnings of $1.34 Per Share, GAAP ...


Chiron Reports 2005 Adjusted Earnings of $1.34 Per Share, GAAP ...
Business Wire (press release), CA - Jan 31, 2006... of upfront payments and royalties, and a settlement with the Scottish National Blood Transfusion Service regarding certain Chiron hepatitis C (HCV) and HIV ...

Transition Therapeutics Increases Ownership Stake in Ellipsis ...
Canada NewsWire (press release), Canada - Feb 6, 2006... include regenerative therapies E1-INT(TM) and GLP1-INT(TM) for the treatment of diabetes, MS-IET for the treatment of multiple sclerosis and HCV-IET for the ...

Schering-Plough's HCV drug gets fast track
United Press International - Jan 30, 2006KENILWORTH, NJ, Jan. 30 (UPI) -- Schering-Plough said Monday the Food and Drug Administration granted fast-track status to its potential hepatitis drug. ...

FDA Grants Fast Track Designation To Oral HCV Protease Inhibitor ...
Medical News Today (press release), UK - Jan 30, 2006... oral hepatitis C protease inhibitor (SCH 503034), currently in Phase II clinical development for the treatment of chronic hepatitis C virus (HCV) infection. ...

Hepatitis C screening urged
Hindu, India - Feb 3, 2006CHENNAI: Experts have called for campaigns to promote screening for the Hepatitis C Virus (HCV), which is currently estimated to have put around 15 million ...

Monday, February 06, 2006


Viral Hepatitis C - Symptoms of Chronic Hepatitis C - WrongDiagnosis.com


Symptoms of Chronic Hepatitis C - WrongDiagnosis.com
Symptoms of Chronic Hepatitis C including medical symptoms and signs of Chronic Hepatitis C, symptoms, incubation period, duration, and correct diagnosis ...

Hepatitis C: FAQ | CDC Viral Hepatitis
Can children receive interferon therapy for chronic hepatitis C? ... It is common for persons with chronic hepatitis C to have a liver enzyme level that ...

Management of Chronic Hepatitis C: Clinical Focus
How well do the results of initial liver biopsy predict measures of disease progression and outcomes of treatment in patients with chronic hepatitis C, ...

Introduction: Chronic Hepatitis C - WrongDiagnosis.com
Information on Chronic Hepatitis C as a medical condition with Chronic Hepatitis C information including symptoms, diagnosis, misdiagnosis, treatment, ...

Viral Hepatitis C - Hepatitis C: The Test


Hepatitis C: The Test
TESTS, Test not listed? A/G Ratio, A1c, ACE, ACT, ACTH, AFB Culture, AFP Maternal, AFP Tumor Markers, Albumin, Aldolase, Aldosterone, Allergies ...

Hepatitis C
The Hepatitis C Virus (HCV). HCV was discovered in 1989 by investigators at Chiron, Inc. Portions of ... They called the new virus hepatitis C virus (HCV). ...

MedlinePlus: Hepatitis C
Related Issues; Coinfection with HIV and Hepatitis C Virus (National Center for HIV, STD, and TB Prevention) Also available in: Spanish ...

Sunday, February 05, 2006


Viral Hepatitis C - Peregrine Announces Acceleration of Its Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program


Peregrine Announces Acceleration of Its Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program
[Press Release] PR Newswire via Yahoo! Finance - Jan 18 4:00 AM
Peregrine Pharmaceuticals, Inc. , a biopharmaceutical company with a portfolio of innovative, clinical-stage product candidates for viral diseases and cancer, today announced that it has accelerated its clinical program for Tarvacin Anti-Viral for the treatment of chronic hepatitis C virus infection .Save to My Web